Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial

Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial

Abstract Background In the phase III ALCYONE trial, daratumumab plus bortezomib/melphalan/prednisone (D-VMP) significantly improved overall response rate and progression-free status compared with VMP alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM). Here, we prese...

Full description

Bibliographic Details
Main Authors: Stefan Knop, Maria-Victoria Mateos, Meletios A. Dimopoulos, Kenshi Suzuki, Andrzej Jakubowiak, Chantal Doyen, Paulo Lucio, Zsolt Nagy, Ganna Usenko, Ludek Pour, Mark Cook, Sebastian Grosicki, Andre Crepaldi, Anna Marina Liberati, Philip Campbell, Tatiana Shelekhova, Sung-Soo Yoon, Genadi Losava, Tomoaki Fujisaki, Mamta Garg, Jianping Wang, Susan Wroblewski, Anupa Kudva, Katharine S. Gries, John Fastenau, Jesus San-Miguel, Michele Cavo
Format: Article
Language:English
Published: BMC 2021-06-01
Series:BMC Cancer
Online Access:https://doi.org/10.1186/s12885-021-08325-2

Internet

https://doi.org/10.1186/s12885-021-08325-2

Similar Items